Global Society of Rare Genitourinary Tumors

International society dedicated to improving the care of rare GU tumors through science and education.

[Philippe spiess @SpiessPhilippe]

Very much hope everyone is having a great start to the weekend. Here is my weekly AI and digital oncology innovation post. Amazing advances are being made!

[Philippe spiess @SpiessPhilippe]

Incredibly proud of this impactful work led by Dr Barbara Melão on behalf of our Global Society of Rare GU Tumors in Nature Reviews Urology @GTumors

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

In 2006 we reported 44 patients with non-muscle-invasive micropapillary bladder cancer treated at MD Anderson. 27 got BCG. At a median 30 months, only 5 of them were disease-free with their bladder in place.

Twenty years on, we went back to the literature to ask whether that picture still holds. New meta-analysis in @EurUrolOncol

🧵1/ @SagarRPatelMD @AmandaMyersMD @UrogerliMD @JoshMeeks @Agarwal_CaB @SWilliams_MD @AndreaNecchi @LAUrology_NL @paolo_gontero @nnavai @JosephBBlack #OncSurgery #ESMO2026

[Karima Oualla, MD,MSc @karima_oualla]

A rich Scientific Day dedicated to the latest advances in oncology in 2026. A great opportunity to share knowledge, exchange expertise, and explore new perspectives in cancer care.
#Morocco
#Oncology2026 #MedicalOncology #CancerCare #ScientificExchange

[Nahuel Paesano @npaesa]

101 experts from 25 countries | New international consensus published in Urologic Oncology.

I am pleased to share our recent publication in Urologic Oncology Seminars and Original Investigations :

“Project international Delphi consensus recommendations for perioperative management of inguinal lymphadenectomy in cancer patients”.

Developed within the Penile Cancer Optimization Initiative (PeCOI), @GTumors and @CAU_URO , this study addresses the prevention and management of perioperative complications following inguinal lymphadenectomy, an area where considerable variability in clinical practice remains.

Key findings:

* 101 experts from 25 countries, representing a broad international and multidisciplinary panel.
* 86 clinical statements evaluated through a two-round modified Delphi process.
* Consensus achieved on 51 statements (59.3%), covering preoperative optimization, lymphatic complications, drain management, antibiotic and thromboembolic prophylaxis, wound complications, and functional rehabilitation.
* Identification of areas of clinical uncertainty requiring further research and prospective validation.

This study provides practical, consensus-based recommendations to support the standardization of perioperative care in inguinal lymphadenectomy, particularly relevant in penile cancer, where high-quality evidence remains limited.

It has been a privilege to work alongside such an outstanding group of internationally recognized experts, @LuisMedinaMD, @drmarcostobias , @jteoh_hk , Amandeep Arora , @drgaganprakash , @DoctorSotelo , and @SpiessPhilippe , as well as all the specialists who contributed to this international consensus.

My sincere thanks to everyone involved, with special thanks to Philippe Spiess, Marcos Tobias-Machado, @ARRODRIGUEZMD , and Luis G. Medina for their support and trust throughout this project.

🙏 @dr_romero_otero @JustoQuintas @RicardoBrime @DrFelixGuerrero @DavidCarracedoC @TouijerKarim @rojo_esther @DrGhaliBelkahia Belkahia Clara Briand Barriga @José Miguel Pérez Ruiz Facundo Barrientos Moll Agustín Fraile Poblador @ROC_Urologia

Published in: Urologic Oncology: Seminars and Original Investigations, 2026.

Full article: https://t.co/1yVY65r45L

#UrologicOncology #PenileCancer #PeCOI #DelphiConsensus #InternationalCollaboration #ROCClinic

[Luis G. Medina @LuisMedinaMD]

Sharing our latest publication in @NatRevUrol

We discuss the importance of standardized complication reporting following inguinal lymph node dissection and the role of the CALI classification.

Special thanks to: @DoctorSotelo @SpiessPhilippe @Cacciamani_MD and @pablopuente07

https://t.co/3rFbqUGOUh

@USC_Urology @MUSC_UroOnc @GTumors @SUO_YUO @UroOnc @arefsayeghs

[gaganprakash @drgaganprakash]

Standardise & Validate : key steps when transitioning from template dissections to DSNB for cN0 penile Ca @urosogo @usiboe @usioffice @GTumors @orchidcancer @tatamencan @YAUpenile_tesCa @PenileCancerr @CurtisPettaway1 @BandiniMd @MaartenAlbersen @SpiessPhilippe @LuisMedinaMD

[Urology Times @UrologyTimes]

We’re excited to announce our new partnership with the Global Society of Rare Genitourinary Tumors (GSRGT)! 

Dr. Philippe Spiess, President and Founder of GSRGT, shared his excitement for this new partnership “... how the GSRGT can expand his outreach in a collaboration with the Urology Times for whom I have had a high regard for many years in the great quality work and impact you have on the urology community and our patients. It would be an honor to explore these next steps together.” 

We’re grateful for the kind words and excited for what we’ll accomplish together in support of the urology community.

@LuisMedinaMD @SpiessPhilippe @AndreaNecchi

[Global Society of Rare Genitourinary Tumors @GTumors]

We are excited to announce a new strategic partnership between the GSRGT and Urology Times!

Together, we aim to advance education, share expert insights, and raise awareness of rare GU malignancies.

Stay tuned for more!

@SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @CAU_URO @JadChahoud @benristau @PGrivasMDPhD @spsutkaMD @LuisMedinaMD @herneygarcia @AndreaNecchi @apolo_andrea @VedangMurthy
@ARRODRIGUEZMD @montypal @UrogerliMD @dramandeeparora @CurtisPettaway1 @karima_oualla @UrologyTimes

[Global Society of Rare Genitourinary Tumors @GTumors]

🚨 Divergent Differentiation & Histologic Subtypes in UTUC

👥 3,441 patients from 22 institutions undergoing radical nephroureterectomy.

🔬 Divergent differentiation showed outcomes comparable to stage-matched pure urothelial carcinoma, while histological subtypes were associated with particularly unfavorable outcomes, emphasizing the importance of pathological charecterization. 🎯

Congratulations to the authors for multi-institutional collaborative effort!

🔗 https://t.co/MogPYXrPKU

@PallaufM @potretzke @SBoorjian @MRoupret @Hoomandjaladat @alirezaghoreifi @DrShariat @Ric_Campi @nirmishsingla @UrolOncol

[Vedang Murthy @VedangMurthy]

Some moments in any academic life are defining... One near the top is being invited to deliver the visiting prof grand rounds to the bright and curious minds of the @HarvardRadOnc residents!

Showered with love and warmth Hope you enjoyed as much as I did. 🙏🏼 @DrPaulNguyen

[Global Society of Rare Genitourinary Tumors @GTumors]

@katy_beckermann Thank you @katy_beckermann !

[Global Society of Rare Genitourinary Tumors @GTumors]

To mark Penile Cancer Awareness Day, the GSRGT is proud to officially launch PCARE — our new patient advocacy initiative supporting people affected by #PenileCancer.

If you are a patient or caregiver looking for support or guidance, please contact us at [email protected] 📩

Special thanks to @SpiessPhilippe, @LuisMedinaMD, and @JadChahoud for bringing this initiative to life.

@drgaganprakash @npaesa @CMercinelli @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @herneygarcia @PGrivasMDPhD @UroDocAsh @spsutkaMD @montypal @shilpaonc @orchidcancer @karima_oualla @VedangMurthy @UrogerliMD

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🧬 Are we testing broadly enough for inherited cancer risk in urinary tract cancers?

A new study reports pathogenic/likely pathogenic germline variants in ~9% of patients with urinary tract cancers.

What stands out even more:

⚠️ More than one-third of carriers would have been missed by current guideline-based testing criteria.

That raises an important question for daily practice:

Should germline testing become broader and less dependent on traditional clinical selection criteria in GU cancers?

🎯 Clinical takeaway: if current criteria miss a substantial proportion of carriers, we may need to rethink who gets tested — not only for the patient, but also for relatives who may carry the same inherited risk.

Congratulations to the authors for this important work 👏

🔗 https://t.co/mJPl9cxS1I.…

#GUOncology #UrothelialCancer #GermlineTesting #GeneticTesting #PrecisionOncology

[Global Society of Rare Genitourinary Tumors @GTumors]

🚨 Germline Variants in Urinary Tract Cancers

Pathogenic/likely pathogenic germline variants in approximately 9% of patients.

More than one-third of carriers would have been missed by current guideline-based testing

Congratulations and thank you to the authors for this work!

🔗 https://t.co/hpQQdoIgFf

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Expanding our Team to 🇪🇸 and 🇺🇦 with residents and students in collaboration with @docjavip @Maroto5Pablo @HospitalSantPau @SanRaffaeleMI @MyUniSR #VladyKasyanenko @MariaCotainaMD #SilviaReparaz #Madrid #Barcelona #Clasico in Milan
All of them put under @MyUniSR DNA!

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Contemporary outcomes of salvage high-dose chemotherapy in advanced germ cell tumors: an analysis of the cellular therapy and immunobiology working party of the @TheEBMT_CTIWP @ESMO_Open @myESMO @vale_tateo @Anto_cigliola @CMercinelli @BrigidaMaiorano @BandiniMd @SanRaffaeleMI @MyUniSR @OncoAlert @urotoday
https://t.co/CBdk458Tou

[Philippe spiess @SpiessPhilippe]

Interesting areas of AI and oncology research and innovation

[Global Society of Rare Genitourinary Tumors @GTumors]

📅 September 20 is the International Penile Cancer Awareness Day.

This year, we have something very special prepared for our penile cancer patients and community.

We can’t wait to share it with you.

Stay tuned! 💙

[YUO @SUO_YUO]

📣 Join us for the inaugural SUO YUO Live Tumor Board!

🗓️ Sept 14 | 8–9 PM ET / 5–6 PM PT
Join Drs. Aditya Bagrodia, Alexandra Drakaki & Muhannad Alsyouf for an interactive, case-based discussion tackling challenging real-world cases across #ProstateCancer, #BladderCancer, #KidneyCancer & #TesticularCancer.

Registration link below👇
https://t.co/MA5v2A1gcl
@WUO_SUO @UroOnc @GTumors @CanUrolAssoc @AmerUrological @IBCG_BladderCA

P.S. Can you see the oopsy in this beautiful AI generated poster? 🧐